Strand and Elan Enter Into Research Collaboration
News Sep 30, 2005
Strand Life Sciences has announced that it has entered into a research collaboration with Elan Pharmaceuticals aimed towards supporting Elan's drug discovery efforts.
This collaboration allows Elan to access Strand's technologies and achieve customized solutions for internal research programs.
The agreement incorporates access to Strand's extensive in silico technology portfolio including predictive modeling for efficacy and ADMET, custom library design, QSAR and pharmacophore modeling, structure based drug design, data and visual mining and consulting experience.
“We believe that Strand's portfolio of technologies are leading edge and look forward to working with them to advance our discovery efforts,” said Dale Schenk, Chief Scientific Officer, Elan Pharmaceuticals.
“We are very excited about this opportunity and are confident that this will be a mutually beneficial relationship,” said Kas Subramanian, Ph.D., CSO of Strand Life Sciences.
“Our existing technology platform coupled with our consulting experience allows us to rapidly develop and deploy tailored solutions that enable decision making.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018